Katia Alves

1.3k total citations
21 papers, 720 citations indexed

About

Katia Alves is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Katia Alves has authored 21 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 11 papers in Epidemiology and 11 papers in Hepatology. Recurrent topics in Katia Alves's work include Hepatitis C virus research (11 papers), HIV/AIDS drug development and treatment (9 papers) and Hepatitis B Virus Studies (5 papers). Katia Alves is often cited by papers focused on Hepatitis C virus research (11 papers), HIV/AIDS drug development and treatment (9 papers) and Hepatitis B Virus Studies (5 papers). Katia Alves collaborates with scholars based in United States, Brazil and Japan. Katia Alves's co-authors include Varun Garg, Rolf van Heeswijk, Jee Eun Lee, Xia Luo, Priya Nadkarni, Gurudatt Chandorkar, Kian Karimi, Patricia Connolly, Rolf P. G. van Heeswijk and Elizabeth J. Keath and has published in prestigious journals such as Hepatology, Journal of Clinical Microbiology and The Journal of Infectious Diseases.

In The Last Decade

Katia Alves

21 papers receiving 702 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katia Alves United States	12	437	399	353	84	73	21	720
Jerry O. Stern United States	16	686 1.6×	808 2.0×	546 1.5×	155 1.8×	91 1.2×	47	1.1k
Mark Sonderup South Africa	18	715 1.6×	671 1.7×	272 0.8×	27 0.3×	61 0.8×	64	1.1k
Pilar García‐Gascó Spain	15	443 1.0×	439 1.1×	418 1.2×	267 3.2×	46 0.6×	19	833
Stéphanie Dominguez France	16	553 1.3×	518 1.3×	590 1.7×	370 4.4×	31 0.4×	39	1.1k
José Vicente Fernández-Montero Spain	21	712 1.6×	749 1.9×	441 1.2×	159 1.9×	25 0.3×	59	1.1k
Álvaro Mena Spain	12	334 0.8×	337 0.8×	241 0.7×	120 1.4×	14 0.2×	52	551
Inmaculada Jiménez-Nàcher Spain	9	235 0.5×	265 0.7×	246 0.7×	86 1.0×	13 0.2×	19	471
Inmaculada Jiménez‐Nácher Spain	18	304 0.7×	299 0.7×	759 2.2×	461 5.5×	41 0.6×	27	992
Vanitha Sekar United States	19	633 1.4×	613 1.5×	954 2.7×	537 6.4×	54 0.7×	33	1.5k
George Hill United States	12	431 1.0×	285 0.7×	193 0.5×	24 0.3×	29 0.4×	21	645

Countries citing papers authored by Katia Alves

Since Specialization

Citations

This map shows the geographic impact of Katia Alves's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katia Alves with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katia Alves more than expected).

Fields of papers citing papers by Katia Alves

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katia Alves. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katia Alves. The network helps show where Katia Alves may publish in the future.

Co-authorship network of co-authors of Katia Alves

This figure shows the co-authorship network connecting the top 25 collaborators of Katia Alves. A scholar is included among the top collaborators of Katia Alves based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katia Alves. Katia Alves is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gane, Edward, Christian Schwabe, Eric Ruby, et al.. (2019). LBP-12-Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers. Journal of Hepatology. 70(1). e146–e147. 2 indexed citations

Zha, Jiuhong, Haoyu Wang, Chen Yu, et al.. (2018). Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. European Journal of Drug Metabolism and Pharmacokinetics. 44(1). 43–52. 1 indexed citations

Sato, Ken, Kazuaki Chayama, Katia Alves, et al.. (2017). Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Advances in Therapy. 34(6). 1449–1465. 9 indexed citations

Kumada, Hiromitsu, Tsunamasa Watanabe, Fumitaka Suzuki, et al.. (2017). Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. Journal of Gastroenterology. 53(4). 566–575. 75 indexed citations

Schnell, Gretja, Rakesh Tripathi, Preethi Krishnan, et al.. (2017). Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir. Journal of Medical Virology. 90(1). 109–119. 11 indexed citations

Zha, Jiuhong, Prajakta Badri, Katia Alves, et al.. (2015). Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects. Clinical Therapeutics. 37(11). 2560–2571. 11 indexed citations

Bisceglie, Adrian M. Di, Mark Sulkowski, Ed Gane, et al.. (2014). VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection. European Journal of Gastroenterology & Hepatology. 26(7). 761–773. 12 indexed citations

Howe, A, Jianmin Long, David C. Nickle, et al.. (2014). Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antiviral Research. 113. 71–78. 19 indexed citations

Rodrigues, José Ariévilo Gurgel, et al.. (2014). <b>Structural features and assessment of zymosan-induced arthritis in rat temporomandibular joint model using sulfated polysaccharide. Acta Scientiarum Biological Sciences. 36(2). 127–127. 8 indexed citations

10.

Garg, Varun, Gurudatt Chandorkar, Yijun Yang, et al.. (2012). The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. British Journal of Clinical Pharmacology. 75(2). 431–439. 35 indexed citations

11.

Garg, Varun, et al.. (2011). Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin. The Journal of Clinical Pharmacology. 52(10). 1566–1573. 49 indexed citations

12.

Lee, Jee Eun, et al.. (2011). Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin. Antimicrobial Agents and Chemotherapy. 55(10). 4569–4574. 57 indexed citations

13.

Garg, Varun, Rolf van Heeswijk, Jee Eun Lee, et al.. (2011). Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 54(1). 20–27. 195 indexed citations

14.

Nascimento, Luiz Fernando Costa, et al.. (2009). Análise espacial das internações por pneumonia na região do Vale do Paraíba (SP). Jornal Brasileiro de Pneumologia. 35(8). 753–758. 11 indexed citations

15.

Sucupira, Maria Cecília Araripe, Marcos Montani Caseiro, Katia Alves, et al.. (2007). High Levels of Primary Antiretroviral Resistance Genotypic Mutations And B/F Recombinants in Santos, Brazil. AIDS Patient Care and STDs. 21(2). 116–128. 41 indexed citations

16.

Durkin, Michelle, Patricia Connolly, Kian Karimi, et al.. (2004). Pathogenic Differences between North American and Latin American Strains of Histoplasma capsulatum var. capsulatum in Experimentally Infected Mice. Journal of Clinical Microbiology. 42(9). 4370–4373. 31 indexed citations

17.

Alves, Katia, Mauro Canzian, & Eric Delwart. (2002). HIV Type 1 Envelope Quasispecies in the Thymus and Lymph Nodes of AIDS Patients. AIDS Research and Human Retroviruses. 18(2). 161–165. 11 indexed citations

18.

Machado, Daisy Maria, Eric Delwart, Ricardo Sobhie Diaz, et al.. (2002). Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors. AIDS. 16(1). 113–119. 26 indexed citations

19.

Karimi, Kian, L. Joseph Wheat, Patricia Connolly, et al.. (2002). Differences in Histoplasmosis in Patients with Acquired Immunodeficiency Syndrome in the United States and Brazil. The Journal of Infectious Diseases. 186(11). 1655–1660. 84 indexed citations

20.

Alves, Katia. (1998). Histoplasmose disseminada e síndrome de imunodeficiência adquirida. Estudo clínico-laboratorial de 28 casos. Revista da Sociedade Brasileira de Medicina Tropical. 31(5). 505–505. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact